Sarcoma: open trials in Japan

15 open trials have a site in Japan. Registry data; only the trial team decides who can take part.

NCT04557449
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Trial Treatment · Phase 1/2 · Pfizer
National Cancer Center Hospital East, Kashiwa
Registry updated 2026-10-28
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Nippon Medical School Hospital ( Site 3306), Bunkyo · Chiba University Hospital ( Site 3322), Chiba · National Hospital Organization Kyushu Cancer Center ( Site 3316), Fukuoka · Kansai Medical University Hospital ( Site 3312), Hirakata · Hiroshima City Hiroshima Citizens Hospital ( Site 3314), Hiroshima · Kanazawa University Hospital ( Site 3308), Kanazawa · National Cancer Center Hospital East ( Site 3303), Kashiwa · St. Marianna University Hospital ( Site 3320), Kawasaki · Saitama Prefectural Cancer Center ( Site 3304), Kitaadachi-gun · Saiseikai Kumamoto Hospital ( Site 3318), Kumamoto · Kurume University Hospital ( Site 3317), Kurume · Saiseikai Matsusaka Municipal Hospital ( Site 3311), Matsusaka · National Hospital Organization Shikoku Cancer Center ( Site 3315), Matsuyam · Nagoya University Hospital ( Site 3309), Nagoya · Miyagi Cancer Center ( Site 3301), Natori-shi · Niigata University Medical & Dental Hospital ( Site 3323), Niigata · Osaka Metropolitan University Hospital ( Site 3321), Osaka · Gunma Prefectural Cancer Center ( Site 3302), Ōta · Toho University Omori Medical Center ( Site 3319), Ōta-ku · Sapporo Medical University Hospital ( Site 3324), Sapporo · Sendai Kousei Hospital ( Site 3300), Sendai · National Center for Global Health and Medicine ( Site 3305), Shinjuku · Tokyo Medical University Hospital ( Site 3307), Shinjuku · Osaka Medical and Pharmaceutical University Hospital ( Site 3313), Takatsuki · Fujita Health University Hospital ( Site 3310), Toyoake
Registry updated 2026-10-26
NCT07541170
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Hoffmann-La Roche
Gifu University Hospital, Gifu · Kobe University Hospital, Hyōgo
Registry updated 2026-10-13
NCT04031677
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Trial Treatment · Phase 3 · European Organisation for Research and Treatment of Cancer - EORTC
Aichi Cancer Center, Chikusa-ku · Osaka International Cancer Institute, Chuo Ku · National Cancer Center Hospital, Chuo Ku · Kyushu University Hospital, Higashiku · Okayama University Hospital, Kita-ku · Cancer Institute Hospital of JFCR, Koto-Ku · Niigata University Medical and Dental Hospital, Niigata · Saitama Medical Center, Jichi Medical University, Saitama · Tohoku University Hospital, Sendai · Nagoya University Hospital, Shōwaku · Yokohama City University Hospital, Yokohama · Kanagawa Cancer Center, Yokohama
Registry updated 2026-10-07
NCT06641908
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Trial Treatment · Phase 1 · EMD Serono Research & Development Institute, Inc.
National Cancer Center Hospital, Chūōku
Registry updated 2026-10-07
NCT07734116
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Trial Treatment · Phase 1/2 · Ono Pharmaceutical Co., Ltd.
Chiba University Hospital, Chiba · National Cancer Center Hospital, Chuo Ku · Kyushu University Hospital, Fukuoka · Hiroshima University Hospital, Hiroshima · Kanazawa University Hospital, Kanazawa · National Cancer Center Hospital East, Kashiwa · Kyoto University Hospital, Kyoto · Okayama University Hospital, Okayama · Osaka International Cancer Institute, Osaka · Kindai University Hospital, Sakai · Hokkaido University Hospital, Sapporo · Tohoku University Hospital, Sendai · Shizuoka Cancer Center, Sunto-gun · Mie University Hospital, Tsu · Yokohama City University Hospital, Yokohama
Registry updated 2026-10-06
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 2 · Bayer
National Cancer Center Hospital, Chuo Ku · National Cancer Center Hospital East (NCCHE) - Kashiwa Campus, Kashiwa · The Cancer Institute Hospital of JFCR, Koto-ku · Aichi Cancer Center Hospital, Nagoya · Kindai University Hospital, Sakai · Hokkaido University Hospital, Sapporo
Registry updated 2026-10-02
NCT07602777
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Trial Treatment · Phase 1/2 · GlaxoSmithKline
GSK Investigational Site, Fukuoka · GSK Investigational Site, Hokkaido · GSK Investigational Site, Tokyo
Registry updated 2026-10-01
NCT07174427
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Trial Treatment · Phase 3 · Takara Bio Inc.
Kyusyu University Hospital, Fukuoka · National Cancer Center Hospital East, Kashiwa · Osaka International Cancer Institute, Osaka
Registry updated 2026-09-28
NCT07630961
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Trial Treatment · Phase 1 · Novartis Pharmaceuticals
Novartis Investigative Site, Chuo Ku
Registry updated 2026-08-27
NCT04999761
AB122 Platform Study
Trial Treatment · Phase 1 · Taiho Pharmaceutical Co., Ltd.
A site selected by Taiho Pharmaceutical Co., Ltd., Aichi · A site selected by Taiho Pharmaceutical Co., Ltd., Chiba · A site selected by Taiho Pharmaceutical Co., Ltd., Ehime · A site selected by Taiho Pharmaceutical Co., Ltd., Hokkaido · A site selected by Taiho Pharmaceutical Co., Ltd., Kanagawa · A site selected by Taiho Pharmaceutical Co., Ltd., Osaka · A site selected by Taiho Pharmaceutical Co., Ltd., Shizuoka · A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo · A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama
Registry updated 2026-08-05
NCT03093116
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Trial Treatment · Phase 1/2 · Turning Point Therapeutics, Inc.
National Cancer Center Hospital, Chuo Ku · National Cancer Center Hospital East, Kashiwa · Nagoya University Hospital, Nagoya · Osaka City General Hospital, Osaka · Osaka International Cancer Institute, Osaka · Hokkaido University Hospital, Sapporo · Ehime University Hospital, Tōon · Kanagawa Cancer Center, Yokohama · Tottori University Hospital, Yonago
Registry updated 2026-05-27
NCT03141021
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Research · Washington University School of Medicine
Nagoya University Hospital, Nagoya
Registry updated 2026-03-09
NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Tanabe Pharma America, Inc.
National Cancer Center Hospital, Chuo Ku · National Cancer Center Hospital East, City
Registry updated 2025-12-11
NCT06603987
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Trial Treatment · Phase 1/2 · Stella Pharma Corporation
ORIX Kouraibashi Bldg. 8F 3-2-7 Kouraibashi Chuo-ku, Osaka
Registry updated 2025-11-19

All Sarcoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error